SLU-PP-332
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
SLU-PP-332 is listed as exercise mimetic (non-peptide).
- •Endurance and metabolic conditioning (research)
Regulatory status: Research chemical (small molecule, not a peptide).
Structure & Properties
Compound: SLU-PP-332; also known as ERR agonist.
Pharmacologic class: Exercise Mimetic (non-peptide).
Known delivery routes: Oral, Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Pan-estrogen-related receptor (ERRα/β/γ) agonist that upregulates oxidative metabolism and mitochondrial biogenesis, mimicking endurance training signaling.
- •Increased mitochondrial density in models
- •Improved fat oxidation and exercise capacity
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Mouse studies showing improved running capacity and fat oxidation
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Zero human safety data
- •Cardiac ERR signaling effects unknown
- •Unregulated sourcing
Contraindications
- •All human use
- •Pregnancy
- •Cardiac disease
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: Not established in humans
Frequency: Not established
Cycling: Not defined.
Oral
For peptides formulated with absorption enhancers (SNAC) or small stable molecules.
Tablet or capsule. Swallow whole with ≤120 mL plain water, on an empty stomach. Wait 30 min before food, other meds, or additional liquid (bioavailability collapses otherwise).
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is SLU-PP-332?
In plain words
SLU-PP-332 is a lab-made research chemical, not a peptide, designed to mimic some signals linked to endurance exercise. It activates switches in cells that increase energy production and the formation of mitochondria [the cells’ energy factories]. Researchers study it for endurance and changes in how the body uses energy. It is not FDA-approved, there are no human safety data, and its effects on heart signaling are unknown.
Technical definition
SLU-PP-332 is a non-peptide small-molecule research chemical classified as an exercise mimetic and a pan-estrogen-related receptor (ERRα/β/γ) agonist. It activates these receptors to upregulate oxidative metabolism and mitochondrial biogenesis, mimicking endurance-training signaling. It is not FDA-approved; evidence is preclinical/observational, with no human safety data and unknown effects on cardiac ERR signaling.
Function
Dosing
Recommended Time of Day
Morning, before activity — exercise-mimetic effect suits daytime dosing.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Not defined.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on SLU-PP-332 and sync them to Vial Lab.
Benefits
- ·Increased mitochondrial density in models
- ·Improved fat oxidation and exercise capacity
Risks
- ·Zero human safety data
- ·Cardiac ERR signaling effects unknown
- ·Unregulated sourcing
Contraindications
- ·All human use
- ·Pregnancy
- ·Cardiac disease
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Research chemical (small molecule, not a peptide)
Veterinary Use (Pets)
No established veterinary protocol for SLU-PP-332. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →